FDA Accepts Aquestive’s Anaphylm Resubmission for Review
Bitget2026/10/15 11:01Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!
A welcome pack worth 6200 USDT for new users! Sign up now!
- FDA accepted Aquestive Therapeutics’ resubmitted application for Anaphylm, a sublingual film for severe allergic reactions, including anaphylaxis.
- The Class 2 review has a target decision date of March 16, 2027.
Disclaimer:
This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aquestive Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610150700PRIMZONEFULLFEED9846192) on October 15, 2026, and is solely responsible for the information contained therein.
0
0
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
DeFi Development Raises CHAD Dividend Yield to 14% on Nasdaq-Listed Solana
Cointime•2026/10/15 15:59
Grayscale Announces New Partnership! 11 Altcoins Listed! Here Are the Details
BitcoinSistemi•2026/10/15 15:51
Mastercard brings stablecoin balances into traditional banking and card payments
Cointelegraph•2026/10/15 15:48
